PAM
VKTX icon

PVG Asset Management’s Viking Therapeutics VKTX Stock Holding History

PVG Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773K Sell
19,818
-35
-0.2% -$1.13K 0.45% 61
2026
Q1 		$588K Buy
19,853
+8,154
+70% +$262K 0.35% 66
2025
Q4 		$412K Sell
11,699
-1,665
-12% -$59K 0.87% 35
2025
Q3 		$351K Buy
13,364
+2,106
+19% +$62.8K 1.29% 28
2025
Q2 		$298K Buy
11,258
+2,205
+24% +$58K 1.02% 34
2025
Q1 		$219K Buy
+9,053
New +$286K 0.95% 32
2022
Q4 		– Sell
-14,810
Closed -$40.3K – 53
2022
Q3 		$40.3K Buy
+14,810
New +$48.5K 0.16% 33

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PVG Asset Management's VKTX Position: Q2 2026 in Review

PVG Asset Management reduced its Viking Therapeutics (VKTX) stake by 0.18% in Q2 2026, selling an estimated $1.13K and leaving 19,818 shares worth $773K. The position accounts for 0.45% of the portfolio, ranked #61.

PVG Asset Management first reported a position in VKTX in Q3 2022 and has held it in 7 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • PVG Asset Management held 19,818 shares of Viking Therapeutics worth $773K as of Q2 2026.
  • PVG Asset Management sold 35 Viking Therapeutics shares in Q2 2026, an estimated $1.13K.
  • Viking Therapeutics made up 0.45% of PVG Asset Management's portfolio in Q2 2026, its #61 holding.
  • PVG Asset Management first reported a position in Viking Therapeutics in Q3 2022 and has held it in 7 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on PVG Asset Management's 13F filing for Q2 2026, filed 1 Jul 2026.